A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Clinical trial NCT01460134 · COMPLETED

Trial details

NCT number: NCT01460134
Sponsor: Celldex Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Marginal Zone B Cell Lymphoma)Any T-cell Malignancy Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)Burkett's Lymphoma Primary Lymphoma of the Central Nervous System

Start date: 2011-10-01
Primary completion: 2015-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.